ABSTRACT
Objective Transcatheter aortic valve replacement (TAVR) is a cine-fluoroscopic guided procedure. The amount of radiation used during the procedure is strictly related with fluoroscopy time (FT) that has been demonstrated to be associated with outcomes and complexity of procedure in percutaneous coronary interventions. The aim of our study is to demonstrate the relationship between FT and short-term outcomes after TAVR.
Methods After splitting 1797 consecutive patients according to tertiles of FT, the composite endpoint early safety (ES) was adjudicated according to Valve Academic Research Consortium (VARC)-2 and -3 consensus documents and the composite endpoints of device success (DS) and technical success (TS) according to VARC-3 criteria.
Results The absence of all outcomes (TS, DS, and ES according to VARC-3 and ES according to VARC-2) was significantly associated with higher FT and this association persisted after propensity score matching analysis. Notwithstanding, after receiver operating characteristic analysis, only the FT cut-offs identified for VARC-3 TS and VARC-2 ES had adequate diagnostic accuracy in identifying the absence of these endpoints.
Conclusions Longer FT is related with peri-procedural and short-term outcomes after the procedure, especially in those that are more complex. A FT duration of more than 30 minutes has an adequate accuracy in identifying VARC-3 technical failure and absence of VARC-2 ES.
What is already known on this topic FT is related with complexity and outcomes in PCI. No data is available about FT and TAVR.
What this study adds FT >30 minutes has an adequate accuracy in identifying VARC-3 technical failure and absence of VARC-2 ES.
How this study might affect research, practice or policy FT that lasts more than 30 minutes in TAVR is linked independently to short-term adverse outcomes after TAVR. A strict follow-up is needed in this procedural setting as FT is a new independent predictor of adverse outcome after TAVR.
Competing Interest Statement
Gaetano Contegiacomo serves as transcatheter heart valve proctor for Abbott; Fortunato Iacovelli and Francesco Spione directly received speaker fees from General Electric Healthcare; the remaining authors have no conflicts of interest to declare.
Clinical Trial
The study was conducted in accordance with the Declara-tion of Helsinki, and approved by the Independent Ethics Committee of the Policlinico University Hospital of Bari, Italy (study number 6244, protocol code 0030669 and date of approval 04th of March 2020).
Funding Statement
This research received no external funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Not Applicable
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was conducted in accordance with the Declara-tion of Helsinki, and approved by the Independent Ethics Committee of the Policlinico University Hospital of Bari, Italy (study number 6244, protocol code 0030669 and date of approval 04th of March 2020).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Not Applicable
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Not Applicable
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Not Applicable
Footnotes
(dr.alessandrocafaro{at}libero.it), (francesco.spio{at}gmail.com), (osvaldoburattini{at}gmail.com), (daniele.df93{at}gmail.com), (alessandroxhelo2{at}gmail.com), (chiara.palmy{at}gmail.com), (maurizio.dalessandro23{at}gmail.com), (vincenzopioamendola{at}icloud.com), (rimmaudoflavio{at}gmail.com), (andrea.guaricci{at}gmail.com), (alessandrosanto.bortone{at}uniba.it), (vpestrichella{at}yahoo.it), (gconteg{at}gmail.com), (tulliotesorio{at}gmail.com), (giuseppe.colonna{at}tin.it), (fortunato.iacovelli{at}gmail.com)
Funding: This research received no external funding.
Institutional Review Board Statement: The study was conducted in accordance with the Declara-tion of Helsinki, and approved by the Independent Ethics Committee of the Policlinico University Hospital of Bari, Italy (study number 6244, protocol code 0030669 and date of approval 04th of March 2020).”
Informed Consent Statement: Informed consent was obtained from all subjects involved in the study.
Conflicts of interest: Gaetano Contegiacomo serves as transcatheter heart valve proctor for Abbott; Fortunato Iacovelli and Francesco Spione directly received speaker fees from General Electric Healthcare; the remaining authors have no conflicts of interest to declare.
Data Availability Statement
Data are accessible with the article (raw data are available upon individual request).